CY1118237T1 - Παραγωγα ν-υδροξυλοσουλφοναμιδιου ως νεοι φυσιολογικα χρησιμοι δοτες νιτροξυλιου - Google Patents

Παραγωγα ν-υδροξυλοσουλφοναμιδιου ως νεοι φυσιολογικα χρησιμοι δοτες νιτροξυλιου

Info

Publication number
CY1118237T1
CY1118237T1 CY20161101084T CY161101084T CY1118237T1 CY 1118237 T1 CY1118237 T1 CY 1118237T1 CY 20161101084 T CY20161101084 T CY 20161101084T CY 161101084 T CY161101084 T CY 161101084T CY 1118237 T1 CY1118237 T1 CY 1118237T1
Authority
CY
Cyprus
Prior art keywords
derivatives
nitroxyl donors
physiologically useful
new physiologically
nitroxyl
Prior art date
Application number
CY20161101084T
Other languages
English (en)
Inventor
John P Toscano
Andrew D Cohen
Stephen Martin Courtney
Lisa Marie Frost
Vincent Jacob Kalish
Frederick Arthur Brookfield
Original Assignee
The Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38284031&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1118237(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Johns Hopkins University filed Critical The Johns Hopkins University
Publication of CY1118237T1 publication Critical patent/CY1118237T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Η εφεύρεση σχετίζεται με παράγωγα N-υδροξυσουλφοναμιδίου που δωρίζουν νιτροξύλιο (ΗΝΟ) υπό φυσιολογικές συνθήκες και είναι χρήσιμα στη θεραπευτική αντιμετώπιση ή/και πρόληψη της έναρξης ή/και ανάπτυξης νόσων ή παθήσεων που ανταποκρίνονται στη θεραπεία με νιτροξύλιο, συμπεριλαμβανομένης της καρδιακής ανεπάρκειας ή/και της βλάβης από ισχαιμία/επαναιμάτωση. Τα καινοτόμα παράγωγα N-υδροξυσουλφοναμιδίου, αποδεσμεύουν ΝΗΟ με ελεγχόμενο ρυθμό υπό φυσιολογικές συνθήκες και ο ρυθμός αποδέσμευσης ΗΝΟ ρυθμίζεται διαφοροποιώντας τη φύση και τη θέση των λειτουργικών ομάδων στα παράγωγα N-υδροξυσουλφοναμιδίου.
CY20161101084T 2006-03-17 2016-10-26 Παραγωγα ν-υδροξυλοσουλφοναμιδιου ως νεοι φυσιολογικα χρησιμοι δοτες νιτροξυλιου CY1118237T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78355606P 2006-03-17 2006-03-17
EP07753345A EP1998761A1 (en) 2006-03-17 2007-03-16 N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
EP12155608.8A EP2489350B1 (en) 2006-03-17 2007-03-16 N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors

Publications (1)

Publication Number Publication Date
CY1118237T1 true CY1118237T1 (el) 2017-06-28

Family

ID=38284031

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20141100166T CY1115314T1 (el) 2006-03-17 2014-02-28 Παραγωγα n-υδροξυλσουλφοναμιδιου ως νεοι φυσιολογικως χρησιμοι δοτες νιτροξυλιου
CY20161100710T CY1117844T1 (el) 2006-03-17 2016-07-20 Παραγωγα ν-υδροξυλοσουλφοναμιδιου ως νεοι φυσιολογικα χρησιμοι δοτες νιτροξυλιου
CY20161101084T CY1118237T1 (el) 2006-03-17 2016-10-26 Παραγωγα ν-υδροξυλοσουλφοναμιδιου ως νεοι φυσιολογικα χρησιμοι δοτες νιτροξυλιου

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20141100166T CY1115314T1 (el) 2006-03-17 2014-02-28 Παραγωγα n-υδροξυλσουλφοναμιδιου ως νεοι φυσιολογικως χρησιμοι δοτες νιτροξυλιου
CY20161100710T CY1117844T1 (el) 2006-03-17 2016-07-20 Παραγωγα ν-υδροξυλοσουλφοναμιδιου ως νεοι φυσιολογικα χρησιμοι δοτες νιτροξυλιου

Country Status (25)

Country Link
US (11) US8030356B2 (el)
EP (8) EP2586434B3 (el)
JP (4) JP5548869B2 (el)
KR (7) KR101878816B1 (el)
CN (4) CN101472576B (el)
AU (4) AU2007227457B2 (el)
BR (1) BRPI0708804B8 (el)
CA (1) CA2645988C (el)
CY (3) CY1115314T1 (el)
DK (2) DK2586435T3 (el)
ES (4) ES2811258T3 (el)
HK (2) HK1174531A1 (el)
HU (2) HUE029309T2 (el)
IL (3) IL193839A (el)
LT (1) LT2586435T (el)
MX (3) MX2008011643A (el)
NO (2) NO342523B1 (el)
NZ (4) NZ595770A (el)
PL (3) PL2586434T3 (el)
PT (3) PT2586434T (el)
RU (2) RU2616292C2 (el)
SG (2) SG170737A1 (el)
SI (3) SI2586434T1 (el)
TR (1) TR200807066T1 (el)
WO (1) WO2007109175A1 (el)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1909779A1 (en) * 2005-06-23 2008-04-16 Johns Hopkins University Thiol-sensitive positive inotropes
SG170737A1 (en) 2006-03-17 2011-05-30 Univ Johns Hopkins N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
SG10201602375PA (en) * 2007-09-26 2016-05-30 Univ Johns Hopkins N-Hydroxylsulfonamide Derivatives As New Physiologically Useful Nitroxyl Donors
MX344316B (es) 2008-05-07 2016-12-13 Cardioxyl Pharmaceuticals Inc Nuevos compuestos nitrosos como donadores de nitroxilo y metodos de uso de los mismos.
WO2010105081A1 (en) * 2009-03-13 2010-09-16 Medtronic, Inc. Method of treating heart failure
WO2011063339A1 (en) 2009-11-23 2011-05-26 Cardioxyl Pharmaceuticals, Inc. Nitroxyl donors for the treatment of pulmonary hypertension
WO2011071951A2 (en) * 2009-12-07 2011-06-16 Johns Hopkins University N-acyloxysulfonamide and n-hydroxy-n-acylsulfonamide derivatives
CN105130855B (zh) * 2009-12-07 2018-05-25 约翰斯霍普金斯大学 二酰基化的羟基胺衍生物及其用途
AU2013201929B2 (en) * 2011-10-17 2015-07-23 The Johns Hopkins University N-substituted hydroxylamine derivatives with carbon-based leaving groups
WO2014070919A1 (en) 2012-11-01 2014-05-08 The Johns Hopkins University Controlled hno release through intramolecular cyclization-elimination
DK3284463T3 (da) * 2013-01-18 2019-10-28 Cardioxyl Pharmaceuticals Inc Nitroxyldonorer med forbedret terapeutisk indeks
EP2764868A1 (en) 2013-02-08 2014-08-13 Friedrich-Alexander-Universität Erlangen-Nürnberg Combination of nitroprusside and a sulfide salt as an HNO-releasing therapeutic for the treatment or prevention of cardiovascular diseases
EP3126329B1 (en) 2014-01-17 2019-05-29 Cardioxyl Pharmaceuticals Inc. N-hydroxymethanesulfonamide nitroxyl donors
WO2015183838A1 (en) 2014-05-27 2015-12-03 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives as nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
EP3148972B1 (en) 2014-05-27 2019-08-21 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
CN107922371B (zh) * 2015-06-26 2022-04-19 约翰斯霍普金斯大学 作为有效的hno供体的具有碳基离去基团的n-取代的异羟肟酸及其用途
KR20180063326A (ko) 2015-10-19 2018-06-11 카르디옥실 파마슈티칼스 인코포레이티드 니트록실 공여자로서의 피라졸론 유도체
KR20180070672A (ko) * 2015-10-19 2018-06-26 카르디옥실 파마슈티칼스 인코포레이티드 니트록실 공여자로서의 n-히드록실술폰아미드 유도체
EP3444245B1 (en) 2016-03-31 2022-02-23 Sumitomo Chemical Company, Limited Heterocyclic compound
JP7194436B2 (ja) 2016-07-28 2022-12-22 ザ ジョンズ ホプキンス ユニバーシティ Ｏ－置換ヒドロキサム酸
KR20190103281A (ko) 2017-01-03 2019-09-04 카르디옥실 파마슈티칼스 인코포레이티드 니트록실 공여 화합물의 투여 방법
CN114230495B (zh) * 2021-11-24 2023-01-06 海南大学 一种氢化亚硝酰供体及其制备方法
CN114195731A (zh) * 2021-11-24 2022-03-18 海南大学 一种氢化亚硝酰供体化合物及其制备方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017976A (en) 1911-08-25 1912-02-20 Rudolph Koch Automatic mail-bag catcher and deliverer.
US3751255A (en) * 1972-03-24 1973-08-07 Eastman Kodak Co Photosensitive and thermosensitive element, composition and process
JPS567710A (en) 1979-06-28 1981-01-27 Sansho Seiyaku Kk Whitening cosmetic
US4539321A (en) 1981-10-26 1985-09-03 William H. Rorer, Inc. 5-Diaza-aryl-3-substituted pyridone compounds
DE3583799D1 (de) 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
US4663351A (en) 1985-08-23 1987-05-05 Berlex Laboratories, Inc. Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
JPH01221371A (ja) * 1988-02-29 1989-09-04 Hokko Chem Ind Co Ltd 環状オキシアミン誘導体の製造方法
JPH01221372A (ja) 1988-03-01 1989-09-04 Hokko Chem Ind Co Ltd 環状アシルヒドロキシルアミン誘導体
JPH0221372A (ja) 1988-07-08 1990-01-24 Sharp Corp はんだ付検査装置
JPH0446169A (ja) * 1990-06-14 1992-02-17 Mitsubishi Petrochem Co Ltd 新規なベンゾフラン誘導体及びそれを含有する除草剤
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
JPH04321671A (ja) * 1991-04-17 1992-11-11 Mitsubishi Petrochem Co Ltd カルバモイルトリアゾール誘導体およびそれを有効成分とする除草剤
ES2089736T3 (es) 1992-10-28 1996-10-01 Shionogi & Co Derivados de bencilideno.
JP2728357B2 (ja) * 1992-10-28 1998-03-18 塩野義製薬株式会社 ベンジリデン誘導体
JPH09165365A (ja) * 1995-09-27 1997-06-24 Ono Pharmaceut Co Ltd スルホンアミド誘導体
JPH10142729A (ja) * 1996-11-05 1998-05-29 Fuji Photo Film Co Ltd 熱現像画像記録材料
TR200001121T2 (tr) 1997-10-24 2000-09-21 Shionogi & Co., Ltd. Antiromatizmal madde.
AU9645798A (en) * 1997-10-24 1999-05-17 Shionogi & Co., Ltd. Antiulcerative
HU228196B1 (en) * 1997-11-12 2013-01-28 Bayer Pharma AG 2-phenyl substituted imidazotriazinones, process for their preparation and pharmaceutical compositions thereof
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
AU4800999A (en) 1998-07-28 2000-02-21 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
LT4727B (lt) 1998-12-29 2000-11-27 Jonas Šarlauskas 5-pakeisti sulfamoilbenzimidazol-2-ilkarbamino rūgščių metilo esteriai, turintys antihelmintinį aktyvumą
ES2251851T3 (es) * 1999-01-13 2006-05-01 Warner-Lambert Company Llc Acidos sulfohidroxamicos y sulfohidroxamatos y su uso com inhibidores mek.
GB9918684D0 (en) * 1999-08-09 1999-10-13 Novartis Ag Organic compounds
JP4792186B2 (ja) 1999-09-01 2011-10-12 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング スルホニルカルボキサミド誘導体、その調製方法および医薬としてのその使用
DOP2000000109A (es) * 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
JP2002072459A (ja) 2000-08-28 2002-03-12 Toyo Gosei Kogyo Kk 光酸発生剤及びそれを含有する感光性樹脂組成物
GB0114223D0 (en) 2001-06-12 2001-08-01 Ici Plc Catalytic oxidation process
US20040038947A1 (en) 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
US6936639B2 (en) 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
US20040121399A1 (en) 2002-12-20 2004-06-24 International Business Machines Corporation Substrate bound linker molecules for the construction of biomolecule microarrays
CA2535117A1 (en) * 2003-08-12 2005-03-03 3M Innovative Properties Company Oxime substituted imidazo-containing compounds
US8598192B2 (en) 2003-11-14 2013-12-03 3M Innovative Properties Company Hydroxylamine substituted imidazoquinolines
JP2007514759A (ja) * 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
AU2005209843B2 (en) 2004-01-30 2012-02-16 The Johns Hopkins University Nitroxyl progenitor compounds and methods of use
WO2006086188A2 (en) 2005-01-31 2006-08-17 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
EP1909779A1 (en) * 2005-06-23 2008-04-16 Johns Hopkins University Thiol-sensitive positive inotropes
SG170737A1 (en) 2006-03-17 2011-05-30 Univ Johns Hopkins N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
SG10201602375PA (en) 2007-09-26 2016-05-30 Univ Johns Hopkins N-Hydroxylsulfonamide Derivatives As New Physiologically Useful Nitroxyl Donors
DK3284463T3 (da) 2013-01-18 2019-10-28 Cardioxyl Pharmaceuticals Inc Nitroxyldonorer med forbedret terapeutisk indeks

Also Published As

Publication number Publication date
JP5548869B2 (ja) 2014-07-16
CN103435524B (zh) 2016-02-10
CN101472576B (zh) 2013-04-17
JP6060139B2 (ja) 2017-01-11
ES2600518T3 (es) 2017-02-09
CN104672115A (zh) 2015-06-03
JP2013144686A (ja) 2013-07-25
US20110306614A1 (en) 2011-12-15
DK2586435T3 (en) 2017-01-09
NZ609381A (en) 2014-10-31
MX368352B (es) 2019-09-30
AU2016201037B2 (en) 2017-09-14
EP2586435B1 (en) 2016-09-14
ES2576292T3 (es) 2016-07-06
HK1174531A1 (en) 2013-06-14
MX342895B (es) 2016-10-18
SI2586434T1 (sl) 2016-09-30
US10829445B2 (en) 2020-11-10
ES2576292T7 (es) 2022-08-24
EP2489350B1 (en) 2013-12-04
RU2011152369A (ru) 2013-06-27
KR101473718B1 (ko) 2014-12-17
KR20090058476A (ko) 2009-06-09
ES2448807T3 (es) 2014-03-17
BRPI0708804B1 (pt) 2019-12-17
CA2645988C (en) 2017-01-10
NO20084355L (no) 2008-12-11
EP3124471A1 (en) 2017-02-01
NO342523B1 (no) 2018-06-04
US11306056B2 (en) 2022-04-19
SG170737A1 (en) 2011-05-30
US20170305847A1 (en) 2017-10-26
EP1998761A1 (en) 2008-12-10
EP2586433A1 (en) 2013-05-01
IL217739A (en) 2016-09-29
EP3124471B1 (en) 2020-06-03
US10179765B2 (en) 2019-01-15
NZ570971A (en) 2011-11-25
JP2017057190A (ja) 2017-03-23
EP2586434A1 (en) 2013-05-01
EP2586434B3 (en) 2022-04-06
NZ700984A (en) 2016-05-27
PT2586434T (pt) 2016-08-05
SI2489350T1 (sl) 2014-05-30
US20140336396A1 (en) 2014-11-13
KR20190096457A (ko) 2019-08-19
US8030356B2 (en) 2011-10-04
US9487498B2 (en) 2016-11-08
KR20180082639A (ko) 2018-07-18
US20200087253A1 (en) 2020-03-19
KR101878816B1 (ko) 2018-07-16
EP2489350A1 (en) 2012-08-22
NO20180624A1 (no) 2008-12-11
IL193839A (en) 2015-04-30
HK1179509A1 (zh) 2013-10-04
DK2489350T3 (en) 2014-03-03
USRE45314E1 (en) 2014-12-30
KR101595781B1 (ko) 2016-02-19
KR20140041941A (ko) 2014-04-04
JP5764590B2 (ja) 2015-08-19
AU2007227457A1 (en) 2007-09-27
AU2016201037A1 (en) 2016-03-10
NZ595770A (en) 2013-04-26
US10487049B2 (en) 2019-11-26
AU2017221796B2 (en) 2019-10-03
US9725410B2 (en) 2017-08-08
BRPI0708804B8 (pt) 2021-05-25
PL2586435T3 (pl) 2017-06-30
EP2596785A1 (en) 2013-05-29
RU2448087C2 (ru) 2012-04-20
AU2013201667A1 (en) 2013-04-11
US20190144380A1 (en) 2019-05-16
PL2489350T3 (pl) 2014-08-29
LT2586435T (lt) 2016-12-12
KR20140147155A (ko) 2014-12-29
CN101472576A (zh) 2009-07-01
RU2616292C2 (ru) 2017-04-14
EP3693363A1 (en) 2020-08-12
US20070299107A1 (en) 2007-12-27
CN104672115B (zh) 2018-11-23
NO343986B1 (no) 2019-08-05
BRPI0708804A2 (pt) 2011-06-14
US20160002156A1 (en) 2016-01-07
JP2015096525A (ja) 2015-05-21
HUE029309T2 (en) 2017-02-28
KR102011703B1 (ko) 2019-08-19
ES2811258T3 (es) 2021-03-11
US9969684B2 (en) 2018-05-15
EP2586434B1 (en) 2016-04-27
SI2586435T1 (sl) 2016-12-30
AU2017221796A1 (en) 2017-09-21
MX2008011643A (es) 2009-02-10
CN109438298B (zh) 2021-10-08
JP2009530303A (ja) 2009-08-27
AU2007227457B2 (en) 2013-03-28
TR200807066T1 (tr) 2009-11-23
IL217739A0 (en) 2012-03-29
KR20150091427A (ko) 2015-08-10
CN103435524A (zh) 2013-12-11
CY1117844T1 (el) 2017-05-17
HUE030920T2 (en) 2017-06-28
EP2586435A1 (en) 2013-05-01
PL2586434T3 (pl) 2016-10-31
IL238271A (en) 2017-05-29
PT2586435T (pt) 2016-12-27
CA2645988A1 (en) 2007-09-27
CN109438298A (zh) 2019-03-08
PT2489350E (pt) 2014-03-10
US20210053915A1 (en) 2021-02-25
CY1115314T1 (el) 2017-01-04
KR20160128447A (ko) 2016-11-07
US20170022154A1 (en) 2017-01-26
WO2007109175A1 (en) 2007-09-27
US9221780B2 (en) 2015-12-29
KR102144926B1 (ko) 2020-08-14
US20180244610A1 (en) 2018-08-30
SG10201503828QA (en) 2016-10-28
RU2008141151A (ru) 2010-04-27

Similar Documents

Publication Publication Date Title
CY1118237T1 (el) Παραγωγα ν-υδροξυλοσουλφοναμιδιου ως νεοι φυσιολογικα χρησιμοι δοτες νιτροξυλιου
CY1124742T1 (el) 4'-φθορο-νουκλεοσιδια, 4'-φθορο-νουκλοεοτιδια και αναλογα αυτων για τη θεραπευτικη αγωγη toy hcv
CY1124446T1 (el) Μορφες δοσολογιας της ρουξολιτινιμπης παρατεταμενης αποδεσμευσης
CY1121724T1 (el) Ενωσεις για την αντιμετωπιση καρκινου
CY1118272T1 (el) Νεες νιτροζο ενωσεις ως δοτες νιτροξυλιου και μεθοδοι χρησης αυτων
CY1117719T1 (el) Παραγωγα αμινοπυριμιδινης ως διαμορφωτες της lrrk2
CY1117776T1 (el) Εναντιομερη ενωσεων σπειρο-οξινδολιου και οι χρησεις τους ως θεραπευτικοι παραγοντες
CY1123991T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1120258T1 (el) Ενωσεις ετεροδικυκλο-υποκατεστημενης-[1,2,4]τριαζολο [1,5-c]κιναζολιν-5-αμινης καταλληλες για αγωγη ή προληψη διαταραχων του κεντρικου νευρικου συστηματος
CY1120450T1 (el) Διαμορφωτες υποδοχεων οιστρογονων και χρησεις εξ'αυτων
CY1118135T1 (el) Παραγωγα 2-(φαινυλο ή πυριδ-3-υλο) αμινοπυριμιδινης ως ρυθμιστες κινασης lrrk2 για τη θεραπευτικη αντιμετωπιση της νοσου του parkinson
CY1122610T1 (el) Αλκοξυ πυραζολια ως ενεργοποιητες διαλυτης γουανυλικης κυκλασης
CY1111758T1 (el) Τρικυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα γλυκοκορτικοειδους
CY1119252T1 (el) Νεα παραγωγα 1-βενζυλο-3 -υδροξυμεθυλινδαζολης και χρηση αυτων στη θεραπεια νοσων που βασιζονται στην εκφραση των cx3cr1 και ρ40
CY1115836T1 (el) Παραγωγα πυραζινονης και η χρηση τους στη θεραπευτικη αντιμετωπιση παθησεων των πνευμονων
CY1118899T1 (el) Ενωσεις ενεδιυνης, συζευγματα εξ’ αυτων, και χρησεις και μεθοδοι δια τουτων
CY1119714T1 (el) Ενωσεις αναστολεων
CY1118129T1 (el) 5-αλκυνυλ-πυριμιδινες
CY1115945T1 (el) Παραγωγα πυραζολοκινολινονης, η παρασκευη τους και η θεραπευτικη τους χρηση
CY1121137T1 (el) Φαρμακευτικα σκευασματα που περιλαμβανουν ανταγωνιστες ccr3
CO6751268A2 (es) Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos
CY1119842T1 (el) Συντηγμενες τρικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις ιντεγκρασης hiv
CY1120008T1 (el) Βενζαμιδια
PE20160120A1 (es) Derivados de nucleosido 4'-fluoro-2'-metilo sustituido
CY1111903T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου με αναλγητικη δραση